Randall A. Oyer, MD, was named the Association of Community Cancer Centers (ACCC) President for 2020-2021 at the ACCC 46th Annual Meeting & Cancer Center Business Summit held March 4-6 in Washington, D.C.
ACCC invites each president to select a theme for their year in office that addresses a timely issue in cancer care through the creation of programs and resources. Dr. Oyer announced that the theme of his presidency will be “Community Oncology Can Close the Gap in Cancer Research.”
“Over the past year ACCC has heard from our members that there are gaps in community research,” said Dr. Oyer. Respondents to ACCC’s “2019 Trending Now in Cancer Care Survey” identified their top three challenges to offering patients with cancer clinical trials as staff resources and training (53%), program infrastructure (50%), and lack of patient understanding of the clinical trials process (46%). Citing these survey findings, Dr. Oyer remarked: “We have a serious imbalance in our clinical trials work. Our patients are in the community, yet the trials are at academic medical centers. And I believe that ACCC is uniquely situated to close this gap.”
Among the plans to achieve this goal outlined by Dr. Oyer were the following:
“We would like to improve our care and access for traditionally underserved communities. We would like to increase sensitivity, awareness, and understanding of the needs specific to geriatric oncology. And we would like to bring precision medicine into the community by understanding how to use the new precision diagnostics and radiology techniques to make sure that our patients have access to these services.”
The resources and tools that will be developed in conjunction with Dr. Oyer’s President’s Theme will be posted to this webpage as they are available.
Presented at the 2020 JADPRO Live Virtual Meeting
Presented at the 2020 ASCO Quality Care Symposium
In the current oncology clinical trials landscape, many barriers
remain to clinical trial enrollment that affect both the oncologist
and the patient. Among these are trial locations, strict eligibility
requirements, insufficient resources to support appropriate clinical
trial education and screening, as well as patient and provider
attitudes about trials.
Research nurse Joannne Riemer, RN, BSN, started her position at Johns Hopkins Medical Institution in 2010. Within six months, she was working with checkpoint inhibitors. From her vantage point in clinical trials research, she discusses the many changes in IO clinical trials patient selection over the last eight years.
Learn how to identify key disparities in clinical trial access for patients with multiple myeloma and explore strategies that can help improve access for underserved communities.
Key results from a recent nationwide survey on the role of APs in cancer clinical research. (November 2, 2020)
Join Nadine J. Barrett as she details strategies to improve clinical trial accrual for racial and ethnic minorities, as well as other at-risk groups. (July 24, 2020)
ACCC President Randall A. Oyer, MD, Medical Director, Oncology Program, Penn Medicine Lancaster General Health, discusses the landscape of oncology clinical trials during the COVID-19 pandemic, includes Q&A. (April 3, 2020)
Oyer Underscores Importance of Innovation and Collaboration in Cancer Care
Ongoing Minority Underrepresentation in Clinical Research Leads to Efforts to Bridge the Divide
Sep 22, 2020
ASCO-ACCC collaboration aims to make clinical trial diversity ‘part of our DNA'
July 31, 2020
Oncologists Scramble to Shift Resources, Develop New Protocols in Response to Novel Coronavirus
Apr 17, 2020
ACCC President Talks Community Oncology and Bridging the Research Gap
March 26, 2020
Challenges for Clinical Trials and Treating Patients With Cancer in Light of the Coronavirus
March 20, 2020
Randall A. Oyer, MD, Becomes President of the Association of Community Cancer Centers
March 11, 2020
Randall Oyer, MD, shares goals as the incoming President of ACCC
March 10, 2020
We sat down with journalist Mary Elizabeth Williams, one of the first patients treated with combination immunotherapy, to discuss her experience as an IO patient and how to bridge communication gaps among patients, doctors, and researchers.